The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksClean Power Hyd Regulatory News (CPH2)

Share Price Information for Clean Power Hyd (CPH2)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12.25
Bid: 12.00
Ask: 12.50
Change: 0.00 (0.00%)
Spread: 0.50 (4.167%)
Open: 12.25
High: 12.25
Low: 12.25
Prev. Close: 12.25
CPH2 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement with KCA Deutag Group

5 Sep 2022 07:00

RNS Number : 1903Y
Clean Power Hydrogen
05 September 2022
 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of UK law by virtue of the European Union (withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

05 September 2022

 

Clean Power Hydrogen Plc

("CPH2", the "Company" or the "Group")

Agreement with KCA Deutag Group

CPH2, the UK-based green hydrogen technology and manufacturing company that has developed the IP-protected Membrane-Free Electrolyser ("MFE") for the production of hydrogen, is pleased to announce that it has entered into a Technology Cooperation Agreement (the "Agreement") with Bentec GmbH, an operating company entity of Kenera Energy Solutions ("Kenera").

Kenera is a newly formed business unit within leading drilling, engineering and technology company KCA Deutag Group. Kenera has been formed as the platform from which the KCA Deutag Group shall grow its offering within hydrocarbon and energy transition markets and is a significant investor in CPH2.

Highlights:

Pursuant to the terms of the Agreement, Kenera will manufacture up to 30 MFE220 units for CPH2 at its manufacturing facility in Germany.

In addition, CPH2 has granted Kenera a non-exclusive license to sell and manufacture CPH2 products in Germany, Scotland, Azerbaijan, Denmark and Norway up to a maximum of 150 MFE units per annum.

CPH2 has also granted Kenera an exclusive license to sell and manufacture CPH2 products across the Middle East up to a maximum level of 2GW (including Oman, Saudi Arabia, United Arab Emirates, Qatar, Kuwait and Iraq).

The Agreement brings together CPH2's innovative MFE technology, which uses cryogenics to separate oxygen from hydrogen, and Kenera's international client base and industry-leading manufacturing capabilities.

The manufacturing arrangements set out in the Agreement will allow an acceleration of the roll out of the Company's technology as the market for hydrogen grows rapidly.

The licensing arrangements, which will be effective for a period of ten years following the completion of the manufacture of an initial 30 MFE units, are a validation of the Company's intellectual property strategy which allows CPH2 to offer proprietary technology to manufacturing partners and resulting in a low-cost business model designed to allow efficient market penetration.

The conclusion of the negotiations with Kenera is the culmination of multiple workstreams that commenced in advance of the Company's successful IPO in February 2022. KCA Deutag chose to invest in the Company at IPO and the collaboration between parties since this point has positioned both parties to take advantage of the rapidly growing hydrogen market, which is forecast to require investment of up to €10 trillion globally by 2050.

The detailed terms of the Agreement provide for ongoing collaboration and support between CPH2 and Kenera, including provision of training and additional resourcing where required, as well as cost and profit-sharing arrangements, backed up by minimum sales targets in exclusive territories.

Jon Duffy, CEO of CPH2 said:

"We are delighted to enter into this agreement with Kenera, whose parent company, KCA Deutag, is not only an investor in CPH2, but is also one of the leading energy sector manufacturing businesses in the world, adding valuable and immediate manufacturing capacity. I am particularly pleased to have additionally signed two sales licensing sub-agreements, which are a capital efficient production method for CPH2, and should will enable a much faster scale up and market penetration of our innovative and disruptive hydrogen electrolyser technology. Interest in this technology continues to grow and our pipeline of opportunities is constantly developing."

Ally Hogg, Head of Commercial for Kenera, commented:

"This collaboration follows our investment into this exciting and ambitious high growth hydrogen business. The relationship with CPH2 adds to our clean energy portfolio and we look forward to actively collaborating with their team as we expand our business in the energy transition space and create value for our stakeholders by delivering our innovative technological solutions, manufacturing and after-sales expertise."

For more information, please contact:

Clean Power Hydrogen Plc

Via Camarco

Jon Duffy, Chief Executive Officer

Cenkos Securities plc - NOMAD & Broker

Neil McDonald

+44 (0)131 220 9771

Peter Lynch

+44 (0)131 220 9772

Adam Rae

+44 (0)131 220 9778

Camarco PR

+ 44(0) 20 3 757 4980

Billy Clegg

Owen Roberts

Fergus Young

 

To find out more, please visit: https://www.cph2.com

Notes to editors

About CPH2

CPH2 is the holding company of Clean Power Hydrogen Group Limited which has almost a decade of dedicated research and product development experience. This experience has resulted in the creation of simple, safe and sustainable technology which is designed to deliver a modular solution to the hydrogen production market in a cost-effective, scalable, reliable and long-lasting manner. The Group's strategic objective is to deliver the lowest LCOH in the market in relation to the production of green hydrogen. The Group's MFE technology is already commercially available and demonstrating cost efficiencies and technological advantages. CPH2 is listed on the AIM market and trades under the ticker LON:CPH2.

About Kenera

Kenera is a business unit within leading drilling, engineering and technology company KCA Deutag. It expands the group's offering in hydrocarbon and energy transition markets and consolidates the skills, competencies and experience of the existing KCA Deutag group with those of Bentec - its land rig and oilfield equipment manufacturer, and RDS - its UK-based engineering and design specialist. Kenera has three dedicated segments covering innovative services, technology & engineering and manufacturing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRUSSKRUNUKRAR
12
Date   Source Headline
19th Apr 20247:00 amRNS2023 Full Year Results
23rd Feb 20247:00 amRNSAwards under Long-Term Incentive Plan
21st Feb 20247:00 amRNSOperational Update
5th Feb 20247:00 amRNSISO Certifications
28th Nov 20237:00 amRNSRevised Agreement with ATOME Energy
20th Nov 20237:00 amRNSChange of Nominated Adviser
2nd Nov 20237:00 amRNSCompany Update
21st Sep 20237:00 amRNSInterim Results
22nd Jun 20237:00 amRNS2023 Save As You Earn Scheme
21st Jun 20231:09 pmRNSResult of AGM
19th Jun 20237:00 amRNSGrant of EMI Options
6th Jun 20237:00 amRNSUpdate on Licence Agreement with GHFG Limited
17th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
28th Apr 202312:16 pmRNSHoldings in Company
26th Apr 20233:26 pmRNSPDMR Dealing
25th Apr 20237:00 amRNSCorporate Presentation
20th Apr 20237:00 amRNSMaiden Financial Results
13th Apr 20237:00 amRNSInvestor Presentation
27th Mar 20237:00 amRNSFabrum Solutions Ltd receives order from Obayashi
16th Mar 20237:00 amRNSPDMR Dealing
27th Feb 20237:00 amRNSLock-in Agreement Extension
8th Feb 20237:00 amRNSSave As You Earn Scheme
31st Jan 20237:00 amRNSManufacturing Agreement with Fabrum Solutions Ltd
26th Jan 20237:00 amRNSAppointment of Chief Technical Officer
22nd Dec 20227:00 amRNSAgreements Signed with Fabrum Solutions Ltd
20th Dec 20221:14 pmRNSHolding(s) in Company
12th Dec 20225:14 pmRNSInvestment in ATOME Energy plc
6th Dec 20227:00 amRNSSenior Management Team Strengthened
22nd Nov 202211:06 amRNSSecond Price Monitoring Extn
22nd Nov 202211:00 amRNSPrice Monitoring Extension
22nd Nov 20229:00 amRNSPrice Monitoring Extension
22nd Nov 20227:00 amRNSOperational Update
4th Oct 20224:41 pmRNSSecond Price Monitoring Extn
4th Oct 20224:35 pmRNSPrice Monitoring Extension
23rd Sep 20227:00 amRNSInterim results
23rd Sep 20227:00 amRNSInterim results
7th Sep 20224:45 pmRNSHolding(s) in Company
5th Sep 20227:00 amRNSAppointment of James Hobson as CFO
5th Sep 20227:00 amRNSAgreement with KCA Deutag Group
24th Aug 20228:11 amRNSOperational Update
19th Jul 20225:55 pmRNSResult of AGM
19th Jul 20227:45 amRNSLicence Agreement with GHFG Ltd.
23rd Jun 20225:24 pmRNSNotice of 2022 Annual General Meeting
27th May 20227:00 amRNSGroup Annual Report and Financial Statements
29th Apr 202210:16 amRNSOperations Update
4th Apr 202212:15 pmRNSAdditional purchase order from existing customer
21st Mar 20227:00 amRNSNew purchase order from additional customer
21st Mar 20227:00 amRNSOperations Update
2nd Mar 20225:31 pmRNSHolding(s) in Company
1st Mar 20224:41 pmRNSSecond Price Monitoring Extn
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.